HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by la Fougère, C. Articles by Dresel, S. Search for Related Content PubMed PubMed Citation Articles by la Fougère, C. Articles by Dresel, S.

D₂ Receptor Occupancy During High- and Low-Dose Therapy with the Atypical Antipsychotic Amisulpride: A ¹²³I-Iodobenzamide SPECT Study

¹ Department of Nuclear Medicine, University of Munich, Munich, Germany
² Department of Psychiatry, University of Munich, Munich, Germany

View larger version (8K): [in a new window]   FIGURE 1. Specific binding ([STR – BKG]/BKG) of 123I-IBZM in healthy controls and in schizophrenic patients treated with high or low doses of amisulpride.

View larger version (9K): [in a new window]   FIGURE 2. Dose–response relationship between striatal dopamine D2 receptor occupancy ([SBcontrol –SBpatient]/SBcontrol) and daily dose of amisulpride (mg/kg of body weight [b.w.]).

View larger version (10K): [in a new window]   FIGURE 3. Dose–response relationship between striatal dopamine D2 occupancy ([SBcontrol –SBpatient]/SBcontrol) and amisulpride plasma concentration (µg/L).

View larger version (45K): [in a new window]   FIGURE 4. 123I-IBZM SPECT images of dopamine D2 receptor binding at equilibrium: drug-naive schizophrenic patient (A) and schizophrenic patients being treated with 50 mg (B), 300 mg (C), or 800 mg (D) of amisulpride per day.